3,4-Difluoro-2-methoxyphenylboronic acid, CAS 905583-06-4, is an aromatic boronic acid building block used primarily for chemical research and the preparation of more complex organic molecules. I position it as a specialized intermediate for medicinal chemistry, pharmaceutical-intermediate development, and related laboratory synthesis rather than as a finished active pharmaceutical ingredient. Its value comes from the combination of an aryl boronic acid functionality with two fluorine substituents and one methoxy substituent, which can support structure diversification through cross-coupling chemistry. As Maison Chemical, I help buyers confirm identity, documentation, packaging, quantity, and project-specific supply requirements before an order is placed.
This guide is intended for procurement teams, medicinal chemists, process-development groups, contract research organizations, and pharmaceutical-intermediate manufacturers evaluating CAS 905583-06-4. It is also useful for distributors that need a reliable source for a niche fluorinated building block. I focus on practical buying questions, including how to identify the material, where it may fit in a synthesis, which specifications to request, and how to evaluate a supplier without relying on unsupported claims.
Because the compound is a research and synthesis intermediate, the correct purchasing decision depends on the intended reaction, required quantity, quality standard, and documentation package. A small discovery project may need a laboratory-scale amount and basic analytical data, while process development may require a larger quantity, tighter impurity control, and repeatable batch supply. I recommend discussing these requirements before comparing price alone.
The defining feature of 3,4-Difluoro-2-methoxyphenylboronic acid is its aryl boronic acid group. In suitable reaction systems, aryl boronic acids are commonly evaluated as coupling partners for carbon–carbon bond-forming transformations, including Suzuki-type chemistry. The two fluorine atoms and methoxy group provide additional substitution patterns that may be useful when a project requires a specific electronic or steric arrangement.
CAS 905583-06-4 should be treated as the primary identity reference during sourcing. I advise buyers to compare the CAS number, chemical name, structure representation, batch information, and analytical records rather than relying on a product name alone. Similar aromatic boronic acids can have closely related names, so a structure and identity check is an important first step.
This material should not automatically be described as an approved pharmaceutical ingredient, a finished drug, or a substance with a defined clinical use. Its potential role is as a chemical building block or intermediate, and the suitability of any resulting molecule must be established by the customer through its own development, analytical, safety, and regulatory procedures. I therefore use cautious language when discussing applications and do not treat a possible synthetic use as a guaranteed performance claim.
Medicinal chemistry teams may evaluate this compound when they need to introduce a substituted difluoromethoxy aryl fragment into a target structure. A boronic acid group can offer a practical handle for testing different coupling routes during analog generation. The actual reaction outcome depends on the partner substrate, catalyst system, base, solvent, temperature, work-up, and purification method, so I recommend laboratory validation before scale-up.
In pharmaceutical-intermediate research, the compound may be considered as one step in a longer synthetic route. Buyers should assess not only whether the material reacts in an intended transformation but also whether the impurity profile, residual solvent profile, and lot-to-lot consistency are suitable for the next stage. For regulated or quality-sensitive projects, the customer should define acceptance criteria before requesting a commercial quotation.
Contract research and custom synthesis organizations may use CAS 905583-06-4 for route screening, fragment incorporation, or small-scale preparation of candidate molecules. The most appropriate grade can vary according to whether the material is being used for early reaction discovery or for a more controlled development campaign. I can discuss the intended use and help determine which technical documents should accompany the inquiry.
For this product, “type” usually refers less to a different chemical form and more to the supply format, quantity, packaging, and quality documentation requested by the buyer. A laboratory project may ask for a small research quantity, while a manufacturing-oriented buyer may request a larger batch or repeated supply schedule. I do not recommend assuming that a larger package automatically has the same documentation or release criteria as a research sample.
You will get efficient and thoughtful service from Maison Chemical.
| Buyer requirement | Information to confirm |
|---|---|
| Identity | CAS 905583-06-4, chemical name, structure, and batch reference |
| Quality | Assay method, reported purity, related substances, and analytical basis |
| Physical form | Appearance, color description, and handling or storage guidance |
| Safety and logistics | SDS, packaging details, shipping classification where applicable, and shelf-life information if provided |
I encourage buyers to request the available certificate of analysis, safety data sheet, product specification, and analytical spectrum or chromatographic record where applicable. These documents should be reviewed for consistency with the actual lot offered, not just with a generic product page. If a project requires a particular assay threshold, water limit, residual solvent limit, or impurity control, that requirement should be stated in writing before production or shipment.
First, I ask how the material will be used and what reaction partner will be involved. This helps distinguish a simple screening purchase from a project that needs repeatable supply and additional analytical support. The reaction plan may also determine whether the buyer needs a standard research grade or a customer-defined specification.
Quantity should be discussed using clear stages rather than vague terms such as “small” or “bulk.” For example, a buyer may request quotations for 100 mg, 1 g, and 10 g to compare screening, development, and larger research requirements. These quantities are planning examples, not a claim that every package size is always available, so I confirm current stock and production feasibility separately.
I recommend checking the lot-specific analytical documents and asking which test methods were used. A reported purity percentage has meaning only when the analytical method, reporting basis, and sample identity are understood. Buyers should also distinguish between a typical specification, a release specification, and a customer-specific acceptance criterion.
Price, minimum order quantity, lead time, packaging, payment terms, and shipping conditions should be evaluated together. The lowest unit price may not be the best option if the order creates avoidable documentation gaps or delivery uncertainty. I provide quotations according to the requested quantity, destination, packaging, and technical requirements rather than presenting one universal price.
The commercial cost of CAS 905583-06-4 can vary with order quantity, batch availability, specification, packaging, and destination. A small research order may carry a different unit cost from a planned multi-kilogram requirement, particularly when additional testing or reserved production is needed. I recommend that buyers provide a realistic forecast so the quotation can reflect the actual purchasing scenario.
Minimum order quantity and lead time should be confirmed for each inquiry. If material is available from existing inventory, the process may differ from a made-to-order supply request, but I do not promise a delivery schedule until stock, documentation, and logistics have been checked. For repeat projects, a forecast covering at least three purchasing stages can help both parties plan production and avoid unnecessary interruptions.
As Maison Chemical, I support buyers by clarifying product identity, available documentation, packaging options, quantity requirements, and export arrangements. I can also review a customer specification and indicate which points are standard, which require confirmation, and which may need a custom supply discussion. This approach helps prevent a mismatch between a quotation and the technical needs of the project.
In summary, 3,4-Difluoro-2-methoxyphenylboronic acid CAS 905583-06-4 may be a useful building block when a project requires a difluoro-methoxy-substituted aryl fragment and a boronic acid reaction handle. It is best evaluated as a research or pharmaceutical-intermediate material, not as a finished pharmaceutical product. The right supplier decision depends on confirmed identity, suitable analytical evidence, realistic quantities, and transparent commercial terms.
To begin an inquiry with Maison Chemical, I recommend sending the required quantity, intended application, target specification, destination country, packaging preference, and desired documentation. If you are comparing 100 mg, 1 g, or 10 g research options, state those quantities clearly so I can prepare a relevant quotation. For larger or repeat requirements, include an estimated schedule so I can review supply feasibility and provide practical next steps.
Want more information on 3,4-Difluoro-2-methoxyphenylboronic acid CAS 905583-06-4? Feel free to contact us.